BALCAO · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Oncotelic Therapeutics, Inc. OTLC
17 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
EPS · FY25
$0.59
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
184.0%
Net margin · FY25
—
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
—
Revenue, FY2025 · full 17-year series below
Revenue
Net income
Per share
USD 0.59
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
184.0%
Return on equity, FY2025
ROE
Operating margin—
Net margin—
Return on assets118.8%
Each USD of equity produced 184 cents of profit this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
—
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−65.7%
−3.0%
Net income
+265.7%
EPS, diluted
+289.3%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.44B
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 393.1M
total assets, end of FY2025
Total assetsUSD 393.1M
EquityUSD 262.8M
Gross debtUSD 3.5M
Current ratio0.07×
Equity funds 67% of total assets.
History
17 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
Revenue $B
·
·
0.0
·
·
0.0
·
·
·
·
·
·
0.0
0.0
·
·
·
Operating income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EBITDA $B
·
·
·
·
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
Income tax $B
0.1
·
·
·
·
·
·
·
·
·
·
0.0
0.0
·
·
·
·
Net income $B
0.2
−0.0
−0.0
0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
0.59
−0.01
−0.02
0.01
−0.03
−0.11
−0.11
−0.12
−0.52
−0.51
−0.54
−0.75
−4.67
−5.48
−10.37
−71.60
−13.15
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
184.0
−44.4
−50.1
37.2
−95.2
−66.3
−68.6
−72.0
−229.9
−72.1
−50.2
−72.2
−156.3
−121.1
−545.1
−8739.0
−426.4
Shares out B
0.44
0.41
0.40
0.39
0.38
0.09
0.08
0.01
0.03
0.03
0.03
0.02
0.01
0.00
0.00
0.01
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
47 of 47
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed